

AMENDMENTS TO THE CLAIMS:

1-23. (Canceled)

24. (Previously presented) A method for preventing recurrence of liver cancer for five years, which comprises administering a therapeutically effective amount of activated lymphocytes to a cancer patient in need thereof while performing surgical treatment of liver cancer, resulting in the prevention of recurrence of liver cancer for five years.

25. (Previously presented) The method as set forth in claim 24, wherein said activated lymphocytes are collected from the cancer patient or another cancer patient.

26. (Previously presented) The method as set forth in claim 24, wherein said activated lymphocytes are administered at a concentration of more than 1×10^9 cells/ml.

27. (Previously presented) The method as set forth in claim 24, wherein said activated lymphocytes are cultivated in the presence of solid-phase anti-CD3 antigen and interleukin 2 before administration.

28. (Previously presented) The method as set forth in claim 24, wherein said activated lymphocytes are administered within eight months after commencing said surgical treatment of liver cancer.

29. (Previously presented) The method as set forth in claim 24, wherein said activated lymphocytes are administered at least five or more times within eight months after commencing said surgical treatment of liver cancer.

30. (New) A method for preventing recurrence of cancer for five years, which comprises administering a therapeutically effective amount of activated lymphocytes to a cancer patient in need thereof while performing surgical treatment of cancer, resulting in the prevention of recurrence of cancer for five years.

31. (New) The method as set forth in claim 30, wherein said activated lymphocytes are collected from the cancer patient or another cancer patient.

32. (New) The method as set forth in claim 30, wherein said activated lymphocytes are administered at a concentration of more than 1×10^9 cells/ml.

33. (New) The method as set forth in claim 30, wherein said activated lymphocytes are cultivated in the presence of solid-phase anti-CD3 antigen and interleukin 2 before administration.

34. (New) The method as set forth in claim 30, wherein said activated lymphocytes are administered within eight months after commencing said surgical treatment of cancer.

35. (New) The method as set forth in claim 30, wherein said activated lymphocytes are administered at least five or more times within eight months after commencing said surgical treatment of cancer.